Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the safety and maximum tolerated dose (MTD) of
Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly
(Part 2) to patients with solid tumors.